MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Journal of Antimicrobial Chemotherapy
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

572 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
572 works in the cohort · of 4,299,418page 10 of 12

Labels cover 0 of 572 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 572 of 572 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affaboutunlabeled
Comparison of phenotypic antimicrobial susceptibility testing results and WGS-derived genotypic resistance profiles for a cohort of ESBL-producing <i>Escherichia coli</i> collected from Canadian hospitals: CANWARD 2007–18
Alyssa Golden, James A. Karlowsky, Andrew Walkty, Melanie Baxter, Andrew Denisuik, Melissa McCracken +4 more
2021· article· en· Journal of Antimicrobial Chemotherapy· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
8
citations
affunlabeled
Gemifloxacin: survival of the fittest
Lionel A. Mandell
2000· review· en· Journal of Antimicrobial Chemotherapy· Medicine
machine prediction:candidate · noneconsensus · none
8
citations
fundno affno abstractunlabeled
Carbapenem resistance in Bacteroides fragilis
Lei Ang, N. Brenwald, Rebecca Walker, J. M. Andrews, A.P. Fraise
2007· letter· en· Journal of Antimicrobial Chemotherapy· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
8
citations
affno abstractunlabeled
Reply
Joseph M. Blondeau
2000· article· fr· Journal of Antimicrobial Chemotherapy
machine prediction:candidate · insufficient_payloadconsensus · none
7
citations
affaboutno abstractunlabeled
Report of a KPC-producing Pseudomonas aeruginosa isolate in Canada
Andrew Walkty, David C. Alexander, James A. Karlowsky, Kim Nichol, John M. Embil
2019· letter· en· Journal of Antimicrobial Chemotherapy· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
6
citations
afffundunlabeled
Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum  -lactamases, AmpC  -lactamases and reduced susceptibility to carbapenems using an in vitro model
George G. Zhanel, Patricia J. Baudry, Franil Tailor, Leonie Cox, D. J. Hoban, James A. Karlowsky
2009· article· en· Journal of Antimicrobial Chemotherapy· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
5
citations

How this was built: Screen · Findings · About